

DT01 Rec'd PCT/PTC 1 7 DEC 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In	re application of:	Dodic et al.									
Se	erial No.:	To Be Assigned	Group Art Unit:								
Fi	le Date:	Concurrently Herewith	Examiner:								
Fo	or:	Phenyloxyalkanonic Acid De	rivatives as HPPAR Activators								
P.	irector of the U.S. Pa O. Box 1450 lexandria, VA 22313	tent and Trademark Office -1450									
INFORMATION DISCLOSURE STATEMENT											
Ex	Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97										
	[] Copies of the references are enclosed: [] Copies of the references were submitted in parent application										
A. [X] The Information Disclosure Statement submitted herewith is being filed within three more filing date of the above application or date of entry into the national stage of an internat application or before the mailing date of a first Office action on the merits, whichever e occurs last. 37 CFR 1.97(b).											
	OR [] The Information Disclosure Statement submitted herewith is being filed before the mailin of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).										
В.	filing date an internat event occu (1) a	of the above application or the									
	Statement		information contained in this Information Disclosure om a foreign patent office in a counterpart foreign or to the filing of this statement.								
		lects the option to pay the fee set Statement under § 1.97(c) (\$180.	forth in 37 CFR 1.17(p) for submission of an Information 00).								
C.	[] The Inform	nation Disclosure Statement trans	smitted herewith is being filed after a final action under §								

1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International

In accordance with the requirements of 37 CFR 1.97(d):

Publication No.

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- [] A duplicate copy of this paper is attached.

Respectfully Submitted,

Robert H. Brink

Registration No. 36,094

Date: 17 December 2004

GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-3323 Facsimile: (919) 483-7988

				TATTODNEY DO	CLETANO	10.15	 X 5 4 /
FORM PTO-14		n - mna enam	ATTORNEY DOCKET NO. PF4813USW		To Be Assigned		
INFORMATIC	ON DISCLOSURE ST	TATEMENT		APPLICANT: Dodic et al.			
				FILING DATE:		GROUP	
				Concurrently Her	ewith	GROOI	
		U.S. I	PATENT D	OCUMENTS			
		T	Ť T			T	Filing Date
Examiner Initials	Patent Number	Issue Date		Name	Class	Subclass	If Appropriate
		T				T	
						T	T
			1			T	
			1				
		1	1				
			1				
			1				
		†	1				
		C	Continue on p	page			
				T DOCUMENTS			
	Document	Publication					Translation
1	Number	Date		Country	Class	Subclass	Yes No
	WO 01/40207	June 7, 2001	WIPO	-			
	WO 02/46174	June 13, 2002	WIPO				
	WO 02/14291	Feb. 21, 2002	WIPO				
	EP 1067109	Jan. 10, 2001	EUROPE			1	
	WO 02/059098	Aug. 1, 2002	WIPO			†	1
		1	 			1	
			 			†	+
	_	+	+			1	1
			+			+	†
 		+	 			+	—
			Continue on p				
	OTHER DOCU	MENTS (Includi	no Author.	Title, Journal-Dat	te. Page Numb	er. Etc.)	
	Official Co.	MENTE (Inches	ilg mumo.,	1110,000	10, 1 mg - 1	21, 211,	
	-,-						
							
							
							
-							
							-
							
			· · · · ·				
			Continue on	nage			
EXAMINER			Johnniac on	page	DATE CO	ONSIDERED	
FXAMINER: I	Initial if citation consider	ered, whether or	not citation	is in conformance v	vith MPEP § 60'	9; Draw line the	rough citation
D2 11 11 11 1 12 1 1	milia. Il vitation cono.	,			U	•	_ ,

if not in conformance and not considered. Include copy of this form with next communication to the applicant.